Kondapa Naidu Bobba

Assistant Professor

Biography

Kondapa Naidu Bobba is a decisive, analytical, and innovative professional with over 11 years of research experience in medicinal chemistry and five years of extensive experience in radiopharmaceutical development. His work primarily focuses on developing and clinically translating novel radiopharmaceuticals for cancer diagnosis and therapy. His research includes incorporating novel linker methodologies to improve imaging and therapeutic outcomes. Additionally, he is deeply interested in identifying new cancer targets and concurrently developing radiotheranostics for both imaging and therapeutic applications. He has authored more than 25 publications and has led successful funding proposals from various agencies.

Research

Bobba's research is at the forefront of radiopharmaceutical development for cancer diagnosis and therapy. His work encompasses synthesizing and evaluating new radiotracers and the development of radiotheranostic for molecular imaging and therapeutic applications. His major research focuses on using novel chemistry techniques to improve tumor-to-background ratios, enhance therapeutic efficacy, and reduce off-target toxicities.

Molecular Imaging and Radiotheranostic

• Development of novel radiopharmaceuticals using PET radioisotopes (Cu-64, Zr-89, I-124/131, Ce-134, F-18, C-11) and therapeutic isotopes (Lu-177, Ac-225, Th-227) to develop single molecular platforms for imaging and therapy.
• Synthesis and modification of bifunctional chelators for radiolabeling with immunoconjugates, peptides, and small molecules for radiotheranostic applications.
• Specialization in the clinical translation of radiopharmaceuticals for first-in-human studies.
• Utilizing novel linker methodologies to reduce off-target toxicity and maximize the therapeutic efficacy of targeted alpha therapies.

Fluorescent probes and theranostics

• Design and synthesize fluorescent probes for early diagnosis of reactive oxygen/nitrogen species such as Hydrogen sulfide, Nitric oxide, etc.
• Development of theranostic probes for targeted drug delivery and imaging in cancer therapy.

Medicinal chemistry

• Total 11 years of research experience in synthetic organic chemistry/medicinal chemistry at various pharmaceutical and contract research organizations. Having as experience as a team lead of more than three years.
• Extensive experience synthesizing complex organic molecules, including pyrroles, pyrimidines, amino acids, and spiro compounds.
• Expertise in various reactions such as Sharpless asymmetric amino hydroxylation, diazotization, nitration, bromination, aldol condensations, Diels-Alder, Grignard, and epoxidation.

Education

• PhD in Chemcialbiology, Department of Sciences, Amrita Vishwa Vidyapeetham, Coimbatore, India, 2018
• MS in Chemistry, Maulana Azad College, Dr. B.A. Marathwada University, Aurangabad, India, 2003
• BS in Chemistry, Sri Venkateswara University, Tirupati, India, 2001

Professional Service

• Invited Talk: "Recent Advances in Radiometals for Companion Imaging Radiopharmaceuticals" at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Mid-Winter Meeting, January 26-28, 2023, San Francisco, USA
• Session Chair: Multimodality Imaging & Radiopharmaceutical Technologies, iSRS 2023, May 22-26, Honolulu, USA
• Abstract Reviewer for iSRS, SNMMI, and WMIC conferences
• Peer reviewer for over ten international journals, including the European Journal of Nuclear Medicine and Molecular Imaging, Journal of Medicinal Chemistry, and ACS Applied Biomaterials
• Topic Editor for "Recent Advances in Radiotheranostics" at Frontiers in Nuclear Medicine

Awards and Recognitions

• Ones to Watch, 2024 SNMMI Annual Meeting
• CMIIT Young Investigator Award, 2024 SNMMI Annual Meeting

Publications

To view a complete list of Bobba's publications, view his Google Scholar profile.

• “PSMA Targeted StarPEG Nanocarrier for Radioligand Imaging and Therapy of Prostate Cancer” Niranjan Meher, Gary W. Ashley, Kondapa Naidu Bobba, Anju Wadhwa, Anil P. Bidkar, Chandrashekhar Dasari, Changhua Mu, Juan A. Camara Serrano, Rahul Aggarwal, Nancy Greenland, Adam Oskowitz, David M. Wilson, Youngho Seo, Daniel V. Santi, Henry F. VanBrocklin and Robert R. Flavell, Adv. Healthcare Mater. 2024, 2304618.
• “A technique to quantify sub-microcurie biodistributions with a collimator less detector” Javier Caravaca, Kondapa Naidu Bobba, Robin Peter, Grant T. Gullberg, Member, Anil P. Bidkar, Robert R. Flavell, Youngho Seo, IEEE TRANSACTIONS ON MEDICAL IMAGING, 2024, Accepted.
• “Peptidoglycan-Targeted [18F]3,3,3-Trifluoro-d-alanine Tracer for Imaging Bacterial Infection” Alexandre M. Sorlin, Marina López-Álvarez, Jacob Biboy, Joe Gray, Sarah J. Rabbitt, Junaid Ur Rahim, Sang Hee Lee, Kondapa Naidu Bobba, Joseph Blecha, Mathew F.L. Parker, Robert R. Flavell, Joanne Engel, Michael Ohliger, Waldemar Vollmer, and David M. Wilson, JACS Au, 2024, 4, 1039–1047.
• “Development of CD46 Targeted Alpha Theranostics in Prostate Cancer using 134Ce/225Ac-Macropa-PEG4-YS5” Kondapa Naidu Bobba, Anil P. Bidkar, Anju Wadhwa, Niranjan Meher, Suchi Drona, Alex Sorlin, Scott Bidlingmaier, Li Zhang, David M. Wilson, Emily Chan, Nancy Greenland, Rahul Aggarwal, Henry F. VanBrocklin, Jiang He, Jonathan Chou, Youngho Seo, Bin Liu, Robert R. Flavell, Theranostics, 2024, 14, 1344-1360.
• “CD46-targeted theranostics for Positron Emission Tomography and 225Ac-radiopharmaceutical Therapy of Multiple” Myeloma Anju Wadhwa, Sinan Wang, Bonell Patino Escobar, Anil P. Bidkar, Kondapa Naidu Bobba, Emily Chan, Niranjan Meher, Scott Bidlingmaier, Suchi Drona, Huimin Geng, Vishesh Sarin, Henry F. VanBrocklin, David M. Wilson, Jiang He, Li Zhang, Veronica Steri, Sandy Wong, Tom Martin, Youngho Seo, Bin Liu, Arun P. Wiita, Robert R. Flavell, Clin. Cancer Res. 2024, 30, 1009-1021.
• "Imaging the bacterial cell wall using N-acetyl muramic acid-derived positron emission tomography radiotracers" Lee Sang Hee, Kim Jung, López-Álvarez Marina, Wang Chao, Sorlin Alexandre; Bobba Kondapa Naidu, Pichardo Gonzalez Priamo, Blecha Joseph, Seo Youngho, Flavell Robert, Engel Joanne, Ohliger Michael, Wilson David, ACS Sens. 2023, 22, 8, 4554-4565.
• Coded Aperture and Compton Imaging for the Development of Targeted Alpha-Particle Therapy” Emily Frame, Kondapa Naidu Bobba, Donald L Gunter, et al., Medical Physics, 2023, 1-15.
• Chemoenzymatic syntheses of positron-labeled disaccharides from [18F]FDG yield potent sensors of living bacteria in vivo, Alexandre M. Sorlin, Marina López-Álvarez, Sarah J. Rabbitt, Aryn A. Alalnizi, Rebecca Shuere, Kondapa Naidu Bobba, Joseph Blecha, Sasank Sakhamuri, Michael Evans, Dima A. Hammoud, Kenneth W. Bayles, Robert R. Flavell, Oren S. Rosenberg, Renuka Sriram, Joanne Engel, Michael A. Ohliger, James Fraser, David M. Wilson, J. Am. Chem. Soc. 2023, 145, 17632–17642.
• “Covalent proteins as targeted radionuclide therapies enhance antitumor effects” Paul C. Klauser, Shalini Chopra, Li Cao, Kondapa Naidu Bobba, Bingchen Yu, Emily Chan, Robert R. Flavell, Michael J. Evans, Lei Wang, ACS Cent. Sci. 2023, 9,1241–1251.
• “Evaluation of Cerium/Lantunum-134 as a PET imaging theranostic pair for 225Ac alpha radiotherapeutics” Kondapa Naidu Bobba, Anil P Bidkar, Cyril Fong, et al., J. Nucl. Med. 2023, 64, 1076-1082.
• “Treatment of prostate cancer with CD46 targeted 225Ac alpha particle radioimmunotherapy”. Clinical cancer research, Anil P Bidkar, Sinan Wang, Kondapa Naidu Bobba, et al. Clin. Cancer Res. 2023, 29, 1916–1928.
• “A short PEG linker alters the in vivo pharmacokinetics of trastuzumab to yield high contrast immune –PET Images” Woonghee Lee, Kondapa Naidu Bobba, Jung Young Kim, Hyun Park, Abhinav Bhise, Wanook Kim, Ki-woong Lee, Subramani Rajkumar, Bora Nam, Kyo Chul Lee, and Jeongsoo Yoo, J. Mater. Chem. B, 2021, 9, 2993-2997.